Summary A rigid corti co-steroid treatment regimen was given to borderline leprosy patients who had recent nerve function loss due to reversal reaction. In order to record nerve function changes objectively a nerve index was used which was based on the results of voluntary muscle testing and sensory testing.
in ulnar nerve function was obtained in 60% and in the median nerve in 67%. Overall improvement was better in BL nerves (85%) when compared with BT nerves (51 %). The results show a more rapid recovery of median nerve function as compared to the ulnar nerve. There was a slightly better recovery of nerve function in previously untreated leprosy patients (69%) as compared to patients who developed nerve function loss while on anti-leprosy treatment (59%).
Nerve damage in reversal reaction is a well-known complication in leprosy.l-4 It occurs in patients in the borderline group of leprosy and may be due to a sudden change in cell-mediated reactivity, although the triggering factor is unknown.5,6
During reversal reaction there is an inflammatory reaction at those sites where leprosybacili are found, that is in the skin and in the nerves. The inflammatory reaction in the nerves, the so-called neuritis, can result in sudden nerve damage. If this reaction is not treated quickly, then permanent nerve function loss may be the result. Drugs such as cortico-steroids should therefore be given to suppress this reaction. The drug in common use is prednisolone. The use of cortico-steroids in leprosy reactional states is not new and they have been used since the start of the use of DDS in leprosy. A group of patients with recent nerve damage were fo llowed in this study during and after a fixed regimen of cortico-steroid treatment.
Materials and Methods
Thirty-six leprosy patients, twenty-four borderline tuberculoid (BT) and twelve borderline lepromatous (BL) were fo llowed up fo r 1 year after they received a 6-month course of prednisolone fo r recent nerve fu nction loss of the ulnar and median nerves. Patients were given 40 mg prednisolone daily fo r the first 2 weeks fo llowed by 30 mg daily fo r the next 2 weeks. Thereafter the dosage was reduced by 5 mg every month. All patients received 100 mg DDS daily as anti-leprosy treatment. A total of 93 nerves, 53 ulnar and 40 median nerves, were fo llowed in this study, an average of 2·6 nerves per patient.
For sensory evaluation we used the technique described by Naafs, 1 6 using a set of bristles with different diameters. The skin was touched with each bristle ( Figure  I ) in five different places. Every stimulus fe lt scored 2 points. Therefore the maximum sensory score for a nerve would be 50 (5 x 5 x 2) points. For muscle testing we used the tests described by Brandsma. 1 7 For the ulnar nerve abduction of the little finger, and fo r the median nerve abduction of the thumb were tested. The scoring, according to the MRC scalel8 was multiplied by a factor 10 thus also giving a maximum score of 50 fo r normal motor fu nction of the nerve. Motor nerve conduction velocity was assessed as described by Naafs.19 Here also a grading scale was developed whereby the score fo r the conduction of the whole nerve was added to the score of the most affected segment of that nerve ( Table 1) .
The Nerve Index is defined as being the VMT score added to the ST score giving a score of 100 for a normal functioning nerve. In the Extended Nerve Index the MeV is added to the Nerve Index.
An increase of at least 15 points was considered an improvement, a loss of more than 15 points deterioration. A change of less than 15 points either way was regarded as status quo. Only patients with nerves with an initial score of 70 or less on the Nerve Index were admitted to the study. In addition the duration of nerve fu nction loss was required to be less than 6 months.
Results
In 29 patients (80%) the nerve fu nction improved; it remained unchanged in fo ur patients and three patients showed deterioration of one nerve.
Thirty-two (60%) of the 53 ulnar nerves improved as did 27 (67%) of the 40 affected median nerves, thus giving a total of 59 (63%) improved nerves. Figure 2 shows the average improvement of these nerves. It will be seen that the median nerve was less affected fr om the start. More marked improvement was also observed in the median nerve during the first 2 months than during the fo llowing 4 months: virtually no fu rther improvement was noted after that period. This contrasts with the ulnar nerve where initial improvement was slower, but still continued after 6 months of treatment. Table 2 relates the recovery to classification of the patients and whether patients were already on treatment when they developed nerve fu nction loss.
Discussion
This study is a preliminary report of a much larger trial of 133 patients and is a report on the first 36 patients who had completed a fo llow-up of I year. The trial was designed to establish the effect of cortico-steroid treatment on neural damage during reversal reaction. 2 0 The anti-leprosy treatment reflects the situation prior to the introduction of multi-drug therapy as recommended by WHO. It has been suggested that cortico-steroids should be given for nerve fu nction loss in reversal reaction at a relatively high dose for a prolonged time to be effective and to prevent recurrence. 1 3 These considerations led to the choice for the cortico-steroid treatment as used in this study. Side-effects can be expected at high dosages of steroids and fo r this reason patients were admitted to hospital during the first 2 The VMT and ST are easy to reproduce and easy to perform. The idea of the Nerve Index is based o.n a publication by Naafs,20 who introduced the Nerve Deficit Index as an index of the nerve function. In the present Nerve Index we have left out the scoring for pain, tenderness and enlargement of the nerve because they are subjective. In our results there is a marked difference between the rates of recovery of the ulnar and median nerves. One explanation might be the difference in anatomical level of nerve involvement. The difference can certainly also be explained by the initial higher VMT score of the median nerve.
When the study was started it was discussed whether the classification of the patient or prior treatment were important to the patient's response to treatment for recent nerve damage. Table 2 shows that BL patients responded more favourably to the treatment than BT patients. The number of BL patients, however, is small and nerve function loss in these patients may recur. A larger observation group and a longer observation time may show more definite results.
There were no major differences between treated and untreated patients.
MeV is useful in a trial like this as another means of objectively assessing nerve function but for the follow-up of nerve function in treatment trials it is not absolutely necessary. No new prognostic indications are added by this method.
The Nerve Index gives a good indication of the nerve function in a leprosy patient as it gives a good picture of the changes of nerve function in treatment trials and is also valuable in the follow-up of nerve function in individual patients.
